Predictive test for Huntington's chorea. 1970

H C Klawans, and G W Paulson, and A Barbeau

UI MeSH Term Description Entries
D009069 Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions. Dyskinesia Syndromes,Etat Marbre,Status Marmoratus,Movement Disorder Syndromes,Dyskinesia Syndrome,Movement Disorder,Movement Disorder Syndrome
D009460 Neurologic Examination Assessment of sensory and motor responses and reflexes that is used to determine impairment of the nervous system. Examination, Neurologic,Neurological Examination,Examination, Neurological,Examinations, Neurologic,Examinations, Neurological,Neurologic Examinations,Neurological Examinations
D009461 Neurologic Manifestations Clinical signs and symptoms caused by nervous system injury or dysfunction. Neurologic Deficits,Neurologic Signs and Symptoms,Focal Neurologic Deficits,Manifestations, Neurologic,Manifestations, Neurological,Neurologic Dysfunction,Neurologic Findings,Neurologic Manifestation,Neurologic Signs,Neurologic Symptoms,Neurological Manifestations,Deficit, Focal Neurologic,Deficit, Neurologic,Deficits, Focal Neurologic,Deficits, Neurologic,Dysfunction, Neurologic,Dysfunctions, Neurologic,Finding, Neurologic,Findings, Neurologic,Focal Neurologic Deficit,Manifestation, Neurologic,Manifestation, Neurological,Neurologic Deficit,Neurologic Deficit, Focal,Neurologic Deficits, Focal,Neurologic Dysfunctions,Neurologic Finding,Neurologic Sign,Neurologic Symptom,Neurological Manifestation,Sign, Neurologic,Signs, Neurologic,Symptom, Neurologic,Symptoms, Neurologic
D011955 Receptors, Drug Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behavior of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified. Drug Receptors,Drug Receptor,Receptor, Drug
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006816 Huntington Disease A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4) Huntington Chorea,Juvenile Huntington Disease,Akinetic-Rigid Variant of Huntington Disease,Chorea, Chronic Progressive Hereditary (Huntington),Chronic Progressive Hereditary Chorea (Huntington),Huntington Chronic Progressive Hereditary Chorea,Huntington Disease, Akinetic-Rigid Variant,Huntington Disease, Juvenile,Huntington Disease, Juvenile-Onset,Huntington Disease, Late Onset,Huntington's Chorea,Huntington's Disease,Juvenile-Onset Huntington Disease,Late-Onset Huntington Disease,Progressive Chorea, Chronic Hereditary (Huntington),Progressive Chorea, Hereditary, Chronic (Huntington),Akinetic Rigid Variant of Huntington Disease,Chorea, Huntington,Chorea, Huntington's,Huntington Disease, Akinetic Rigid Variant,Huntington Disease, Juvenile Onset,Huntington Disease, Late-Onset,Juvenile Onset Huntington Disease,Late Onset Huntington Disease
D013268 Stimulation, Chemical The increase in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Stimulation,Chemical Stimulations,Stimulations, Chemical

Related Publications

H C Klawans, and G W Paulson, and A Barbeau
May 1982, British medical journal (Clinical research ed.),
H C Klawans, and G W Paulson, and A Barbeau
March 1971, The New England journal of medicine,
H C Klawans, and G W Paulson, and A Barbeau
March 1978, British medical journal,
H C Klawans, and G W Paulson, and A Barbeau
April 1978, British medical journal,
H C Klawans, and G W Paulson, and A Barbeau
March 1982, The New England journal of medicine,
H C Klawans, and G W Paulson, and A Barbeau
September 1986, British medical journal (Clinical research ed.),
H C Klawans, and G W Paulson, and A Barbeau
January 1969, Humangenetik,
H C Klawans, and G W Paulson, and A Barbeau
January 1969, Humangenetik,
H C Klawans, and G W Paulson, and A Barbeau
July 1986, British medical journal (Clinical research ed.),
H C Klawans, and G W Paulson, and A Barbeau
May 1971, The New England journal of medicine,
Copied contents to your clipboard!